Market Place
Sourcing Support
Apollo Therapeutics Signs Exclusive License for FGF21/GLP-1 Agonist
12 Nov 2024 //
BUSINESSWIRE
Apollo Therapeutics Partners With Oxford For Drug Discovery And Dev
21 Jul 2024 //
BUSINESSWIRE
Apollo Therapeutics Announces Second Close of Series C Financing
02 Jan 2024 //
BUSINESSWIRE
Apollo Closes $226.5 Million Series C Financing Led by Patient Square Capital
06 Sep 2023 //
BUSINESSWIRE
ICR announces collaboration with Apollo to develop novel cancer drugs
28 Nov 2022 //
PRESS RELEASE
Apollo and The Institute of Cancer Research enter into collaboration
14 Nov 2022 //
BUSINESSWIRE
Apollo lands inflammatory antibody from Avalo for $90M biobucks
01 Aug 2022 //
FIERCEBIOTECH
Apollo Therapeutics and King’s College London collaborate for biology
22 Feb 2022 //
PHARMAFILE
Apollo Therapeutics, King’s College London Enter Into a Strategic Collaboration
22 Feb 2022 //
BUSINESSWIRE
Apollo Appoints Dr. Sanjay Aggarwal as CMO, Opens U.S. Facility
18 Nov 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.